Recombinant Human Lymphocyte antigen 96(LY96),partial CSB-EP013254HU
Specifications
| 20ug / 100ug / 1mg price = 100ug |
Alternative Name(s):
ESOP-1 Protein MD-2
Species: (Organism)
Homo sapiens (Human)
Gene Names:
LY96
Tag info:
N-terminal 10xHis-GST-tagged and C-terminal Myc-tagged
Target Protein AA Sequence:
EAQKQYWVCNSSDASISYTYCDKMQYPISINVNPCIELKRSKGLLHIFYIPRRDLKQLYFNLYITVNTMNLPKRKEVICRGSDDDYSFCRALKGETVNTTISFSFKGIKFSKGKYKCVVEAISGSPEEMLFCLEFVILHQPNSN
Expression Region:
17-160aa
Subcellular Location:
Secreted, extracellular space, Secreted
Tissue Specificity:
Protein Length:
Partial
Pathway:
NF-kappaBsignalingpathway
Mol. Weight:
46.7 kDa
Purity:
Greater than 90% as determined by SDS-PAGE.
Form:
Liquid or Lyophilized powder
Buffer:
If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Research Areas:
Immunology
Function:
Binds bacterial lipopolysaccharide (LPS)
Involvement in disease:
Relevance:
Binds bacterial lipopolysaccharide (LPS) (PubMed:17803912, PubMed:17569869). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response to cell wall components from Gram-positive and Gram-negative bacteria (PubMed:11160242, PubMed:11593030). Enhances TLR4-dependent activation of NF-kappa-B (PubMed:10359581). Cells expressing both LY96 and TLR4, but not TLR4 alone, respond to LPS (PubMed:10359581).
Reconstitution:
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Protein Families:
Reference:
"MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4."Shimazu R., Akashi S., Ogata H., Nagai Y., Fukudome K., Miyake K., Kimoto M.J. Exp. Med. 189:1777-1782(1999)
